Israeli - Kiingereza - Ministry of Health

trima israel pharmaceutical products maabarot ltd - voriconazole - tablets - voriconazole 200 mg - voriconazole - treatment of: invasive aspergillosis, candidemia in non-neutropenic patients, fluconazole-resistant serious invasive candida infections (including c. krusei), serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Israeli - Kiingereza - Ministry of Health

devries & co. ltd - cetrimonium bromide; lidocaine; tyrothricin - lozenges - lidocaine 1 mg; tyrothricin 4 mg; cetrimonium bromide 2 mg - lidocaine - for the relief of pain associated with severe sore throat and mouth infections.

Israeli - Kiingereza - Ministry of Health

isorad ltd, israel - tetrakis copper (i) tetrafluoroborate - lyophilized powder for solution for injection - tetrakis copper (i) tetrafluoroborate 1 mg/vial - this medicinal product is for diagnostic use only. this is indicated for adults. for paediatric population see section 4.2.after radiolabelling with sodium pertechnetate (99mtc) solution, the solution of technetium (99mtc) sestamibi obtained is indicated for:myocardial perfusion scintigraphyfor the detection and localisation of coronary artery disease (angina pectoris and myocardial infarction).assessment of global ventricular function first-pass technique for determination of ejection fraction and/or ecg-triggered, gated spect for evaluation of left ventricular ejection fraction, volumes and regional wall motion.scintimammography for the detection of suspected breast cancerwhen mammography is equivocal, inadequate or indeterminate.localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled to undergo initial surgery of the parathyroid glands.

Israeli - Kiingereza - Ministry of Health

inovamed ltd - paricalcitol - solution for injection - paricalcitol 0.005 mg/ml - paricalcitol - paricalcitol is indicated in adults for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure who are undergoing haemodialysis.

Israeli - Kiingereza - Ministry of Health

rafa laboratories ltd - fingolimod as hydrochloride - capsules - fingolimod as hydrochloride 0.5 mg - fingolimod - treatment of patients with relapsing forms of multiple sclerosis (ms) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Israeli - Kiingereza - Ministry of Health

rafa laboratories ltd - fentanyl as citrate - tablets sublingual - fentanyl as citrate 267 mcg - fentanyl - treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Israeli - Kiingereza - Ministry of Health

rafa laboratories ltd - fentanyl as citrate - tablets sublingual - fentanyl as citrate 267 mcg - fentanyl - treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Israeli - Kiingereza - Ministry of Health

rafa laboratories ltd - fentanyl as citrate - tablets sublingual - fentanyl as citrate 400 mcg - fentanyl - treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Israeli - Kiingereza - Ministry of Health

rafa laboratories ltd - fentanyl as citrate - tablets sublingual - fentanyl as citrate 400 mcg - fentanyl - treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Israeli - Kiingereza - Ministry of Health

rafa laboratories ltd - fentanyl as citrate - tablets sublingual - fentanyl as citrate 533 mcg - fentanyl - treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.